About Corcept Therapeutics
Corcept Therapeutics develops Korlym (mifepristone) for Cushing syndrome and is advancing relacorilant for malignant hypercortisolism and other cortisol-dependent conditions.
📍 Location & Offices
📋 Request a Quote
Send your requirements directly to Corcept Therapeutics. Response typically within 48 hours.
Company Info
TypePublic
StockCORT (NASDAQ)
Founded1998
Employees600
Revenue$690M
HQMenlo Park, USA
